Stratos Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Stratos Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$255K	Hold	5,365	–	–	0.02%	521
2025 Q4	$281K	Hold	5,365	–	–	0.01%	540
2025 Q3	$348K	Sell	5,365 -200	-4%	-$11.5K	0.02%	522
2025 Q2	$271K	Buy	+5,565	New	+$215K	0.01%	567
2025 Q1	–	Sell	-5,440	Closed	-$214K	–	677
2024 Q4	$214K	Sell	5,440 -2	-0%	-$94	0.01%	664
2024 Q3	$256K	Sell	5,442 -1,366	-20%	-$69.3K	0.01%	646
2024 Q2	$368K	Buy	6,808 +25	+0.4%	+$1.45K	0.02%	537
2024 Q1	$462K	Sell	6,783 -82	-1%	-$5.87K	0.03%	476
2023 Q4	$430K	Sell	6,865 -3,696	-35%	-$204K	0.02%	489
2023 Q3	$479K	Buy	10,561 +4,886	+86%	+$252K	0.03%	434
2023 Q2	$319K	Buy	5,675 +105	+2%	+$5.96K	0.02%	503
2023 Q1	$252K	Buy	5,570 +129	+2%	+$6.26K	0.02%	528
2022 Q4	$221K	Buy	+5,441	New	+$289K	0.02%	531

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Stratos Wealth Advisors's CRSP Position: Q1 2026 in Review

Stratos Wealth Advisors held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 5,365 shares worth $255K. The position accounts for 0.02% of the portfolio, ranked #521.

Stratos Wealth Advisors first reported a position in CRSP in Q4 2022 and has held it in 13 quarters since. The position peaked at $479K in Q3 2023. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Stratos Wealth Advisors held 5,365 shares of CRISPR Therapeutics worth $255K as of Q1 2026.
Stratos Wealth Advisors left its CRISPR Therapeutics share count unchanged in Q1 2026.
CRISPR Therapeutics made up 0.02% of Stratos Wealth Advisors's portfolio in Q1 2026, its #521 holding.
Stratos Wealth Advisors first reported a position in CRISPR Therapeutics in Q4 2022 and has held it in 13 quarters since.
Stratos Wealth Advisors's CRISPR Therapeutics position peaked at $479K in Q3 2023.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Stratos Wealth Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.